Nexgel, Inc · NASDAQ:NXGL
Nexgel — Investor Presentation (October 2024)
18 slides from Nexgel's investor presentation, Oct 28, 2024
Slide 1: Investor Presentation October 2024
Investor Presentatio October 2024 Ms @NEXGEL NASDAQ: NXGL » |" /| f
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains certain forward-looking statements, including those relating to the Company's product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and
Slide 3: NEXGEL - Who We Are and What We Do
NEXGEL - Who We Are and What We Do After two decades of creating custom hydrogel Agreements with Multi-Billion solutions for large medical device companies, our Dollar Corporations business today includes the development of patented medical devices, custom/white label oe products, and OTC healthcare
Slide 4: Multiple Products & Applications for Nexgel's Technology
Multiple Products & Applications for Nexgel’s Technology Branded Products Custom & White Label NEXGEL is Bringing proven Proprietary addressing the medical-grade consumer brands importance of technology to and accretive skin integrity OTC and Beauty M&A and overall & Cosmetics for opportunities skin
Slide 5: Competitive Advantage: State-of-the-Art Manufacturing Facilities in NA
Competitive Advantage: 1 of 2 State-of-the-Art Manufacturing Facilities in NA Medical grade technology and facility, providing gels to multi-national device companies for over 20 years with sufficient capacity to fulfill consumer and healthcare segments >1.4 Billion square inches 1 of 2 manufacturin
Slide 6: Converting and Packaging Facility
Converting and Packaging Facility 50% ownership in converting and packaging business in Granbury, Texas + Significant synergies which enable the onboarding of potential finished goods customers along with enhanced combined marketing and outreach efforts + Increased square footage and installed cutti
Slide 7: Hydrogels for Consumer and Medical Applications
Hydrogels for Consumer and Medical Applications + Electron beam technology eliminates the need for harmful chemicals in cross-linking, which, along with our paraben-free formulation, makes our patches the only option for many medical device applications and preferred among consumers * Gentle formula
Slide 8: Current Medical Device Pipeline
Current Medical Device Pipeline Addressing the importance of skin integrity and overall skincare with a medical device ‘ @NEXCEL Raeiiaal | |X /| |
Slide 9: Medical Device Pipeline: Drug Delivery
Medical Device Pipeline: Drug Delivery Potential for Multiple Drug Delivery Applications through Unique Hydrogel Technology Drug Delivery: Diclofenac Patch To treat short-term pain due to preclinical sprains and bruises Drug Delivery: Apremilast Patch Compara dium from NEXGELPaten Atersiowe To treat
Slide 10: Medical Device Pipeline - Surgical Drape
Medical Device Pipeline - Surgical Drape NEXDrape - A “skin friendly” solution for the surgical drape 510(k) market; providing consistent adhesion; greater skin integrity; comfortable removal post surgery; decreased skin irritation. VS IRB study in accordance with FDA designed to measure the efficac
Slide 11: Consumer Health & Beauty
Consumer Health & Beauty Bringing proven medical-grade technology to OTC and B&C for the first time through many new consumer products & applications f @NEXGEL NASDAQ: NXGL lA
Slide 12: NEXGEL Branded Products
NEXGEL Branded Products C@) SilverSeal @NEXGEL NASDAQ: NXGL 12
Slide 13: M&A Strategy: Consumer Brand Acquisition
M&A Strategy: Consumer Brand Acquisition Kenkoderm Skincare Line Silly George Beauty Brand + Acquisition completed in December 2023 + Acquisition completed in May 2024 + Complimentary line of alternative psoriasis treatments + Specialty eye and eyelash consumer product line + Profitable (ttm) and im
Slide 14: Cintas Corporation
Cintas Corporation Cintas is a leading provider of corporate identify uniforms, first aid and safety products and services to over 1 million businesses across North America * Cintas will distribute SilverSeal, NEXGEL's hospital-grade dressing for wounds and burns to its customers in many sectors inc
Slide 15: STADA Arzneimittel AG
STADA Arzneimittel AG Partnership with European leader in consumer health supports expansion of NEXGEL OTC product portfolio * In 2022, STADA generated revenue of EUR 3.8 billion and EBITDA of EUR 885 million. * STADA already focuses on consumer healthcare products, generics and specialty pharm, sel
Slide 16: AbbVie
AbbVie (NYSE: ABBV) CG Converting and Packaging is the exclusive supplier of gel pads to be used with AbbVie’s Rapid Acoustic Pulse device for the improvement in the appearance of cellulite + Allergan Aesthetics, acquired by AbbVie, purchased Soliton, the owner of the Resonic technology, for $550 mi
Slide 17: Revenue Growth / Record for Q3 '24
Revenue Growth / Record for Q3 '24 $3,000 $2.85M, * Preliminary record third quarter 2024 revenue " +133% YOY & +98% QoQ. Revenue Growth : * Growth in 2H of 2024 has exceeded $2,500 expectations for both contract manufacturing and consumer products $2,000 + Q3 to Q4 sequential growth is expected + I
Slide 18: Contact Us
Contact Us Investor Relations: KCSA Strategic Communications Valter Pinto, Managing Director PH: (212) 896-1254 NEXGEL@KCSA.com @NEXCEL NASDAQ; NXGL | a /| ‘